Please assess the completion status of the following clinical trial:

Trial Title: 6-week Safety and PD Study in Adults With NAFLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* BMI at least 28 kg/m2~* Type 2 diabetes and/or metabolic syndrome~Exclusion Criteria:~* Liver disease~* Type 1 diabetes~* Recent heart attack or stroke~* Inability to have an MRI scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- PF-06835919 Low Dose (Type: EXPERIMENTAL): 75 mg once daily
- PF-06835919 High Dose (Type: EXPERIMENTAL): 300 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).